Investment+startup Brief — 2026-06-04

Posted on June 04, 2026 at 07:45 PM

Investment+startup Brief — 2026-06-04

Covering developments published in the 48h to 2026-06-04 19:45:43 (+0800).

Top Stories

1. Ramp notches a $44 billion valuation in fresh financing

  • Bloomberg · 2026-06-04
  • Summary: Expense management and corporate card startup Ramp secured a new funding round that valued the company at $44 billion, marking one of the most significant private-market financings in fintech this year. The deal underscores continued investor appetite for scaled software businesses that combine growth with operational leverage.
  • Why It Matters: Ramp’s pricing resets the bar for late-stage fintech valuations and signals that capital remains available for category leaders despite a selective venture market.
  • URL: https://www.bloomberg.com/news/articles/2026-06-04/ramp-notches-44-billion-valuation-in-new-funding-round

2. Impulse Space raises $500 million to expand spacecraft production

  • TechCrunch · 2026-06-02
  • Summary: Impulse Space announced a $500 million Series D led by 137 Ventures and BANNER VC, with participation from Founders Fund, Lux Capital, and Linse Capital. The company said it will use the capital to build and test more space vehicles and hire up to 200 employees as it expands its in-space mobility platform.
  • Why It Matters: The round is a major indicator that investors are still willing to fund capital-intensive frontier startups when they have defense relevance, technical credibility, and clear government demand.
  • URL: https://techcrunch.com/2026/06/02/rocket-engine-startup-impulse-raises-500-million-to-hire-people-not-ai/

3. Merantix Capital closes a €103 million fund for early-stage AI startups

  • BeBeez International · 2026-06-04
  • Summary: Merantix Capital closed a €103 million fund focused on early-stage AI startups in Europe. The vehicle adds fresh specialist capital to a market where founders are competing for investors with both domain expertise and follow-on capacity.
  • Why It Matters: New fund formation is a leading indicator for startup financing conditions, and this close suggests sustained institutional conviction behind Europe’s AI pipeline.
  • URL: https://bebeez.eu/2026/06/04/german-vc-merantix-capital-closes-e103-million-fund-for-early-stage-ai-startups/

4. Scispot closes an $8 million Series A for life sciences lab software

  • BetaKit · 2026-06-04
  • Summary: Scispot announced an $8 million USD Series A to position its platform as an operating layer for life sciences labs. The company is targeting a segment where software standardization and workflow automation remain early, despite growing biotech digitization needs.
  • Why It Matters: Investors continue to back vertical software with strong workflow lock-in, especially in regulated or data-heavy industries where platform adoption can translate into durable revenue.
  • URL: https://betakit.com/scispot-closes-8-million-usd-series-a-to-become-the-operating-layer-for-life-sciences-labs/

5. Findigs raises $32 million Series C for leasing decisioning

  • Proptech Connect · 2026-06-04
  • Summary: Proptech startup Findigs raised $32 million in Series C funding to expand its leasing decisioning platform. The company operates in a housing workflow category where automation can reduce friction for property managers while improving applicant screening and conversion.
  • Why It Matters: The raise shows that investors still see room for scaled software plays in real estate infrastructure, especially where products can plug directly into transactional decision points.
  • URL: https://proptechconnect.com/findigs-raises-32m-series-c-funding-for-leasing-decisioning/

6. Semble raises £30 million in Series C funding

  • Medical Buyer · 2026-06-04
  • Summary: Healthcare software company Semble raised £30 million in Series C funding to scale its connected care platform. The capital is aimed at expanding product and market reach in a segment where providers are under pressure to modernize clinical and operational workflows.
  • Why It Matters: Healthtech funding remains selective, so later-stage rounds for operating platforms suggest investors are prioritizing companies with clearer enterprise adoption and recurring revenue paths.
  • URL: https://medicalbuyer.co.uk/semble-raises-30m-in-series-c-funding-round/

7. CereVasc secures an oversubscribed $85 million Series C

  • Company announcement · 2026-06-04
  • Summary: CereVasc announced an oversubscribed $85 million Series C financing to advance its eShunt system for treating normal pressure hydrocephalus. The round gives the medtech company additional capital to progress development and clinical execution around a device targeting a significant neurological treatment gap.
  • Why It Matters: Large private financings in medtech signal that investors remain willing to fund differentiated clinical assets, particularly where the technology addresses high-cost unmet care needs.
  • URL: https://cerevasc.com/cerevasc-inc-announces-over-subscribed-85-million-series-c-financing-to-advance-its-novel-eshunt-system-for-the-treatment-of-normal-pressure-hydrocephalus/

8. Lassie raises $35 million in Series A funding

  • FinSMEs · 2026-06-04
  • Summary: Pet insurance startup Lassie raised $35 million in Series A funding as it expands in an insurtech category tied to growing consumer spending on pet care. The company is part of a broader wave of startups trying to pair underwriting with preventative, engagement-led customer models.
  • Why It Matters: Even in a tighter market, investors are still backing category-specific insurance startups when they can combine a large consumer segment with data-driven retention and risk management.
  • URL: https://www.finsmes.com/2026/06/lassie-raises-35m-in-series-a-funding.html

9. Ona Therapeutics raises $86.6 million in Series B funding

  • FinSMEs · 2026-06-04
  • Summary: Oncology-focused biotech Ona Therapeutics raised $86.6 million in Series B funding to advance its pipeline. The financing reflects continuing investor support for therapeutic platforms that can show differentiated science and credible clinical development plans.
  • Why It Matters: Biotech remains one of the few sectors where substantial private rounds can still get done on the strength of technical milestones, making these financings an important read-through on risk appetite.
  • URL: https://www.finsmes.com/2026/06/ona-therapeutics-raises-86-6m-in-series-b-funding.html